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cysteine, which chelates and deposits iron in the cells of 
the globus pallidus.7 Cysteine is ordinarily metabolised in 
the biosynthetic pathway of coenzyme A; however, the 
first step of this pathway, the phosphorylation of dietary 
pantothenate to 4-phosphopantothenate, is prevented in 
PKAN by a mutation in PANK2.2 Cysteine concentrations 
rise as a result and coenzyme A is depleted, and both 
are major regulators of the iron-dependent cell death 
pathway (eg, ferroptosis). Cysteine is the rate-limiting 
substrate for glutathione synthesis, which is the necessary 
cofactor for glutathione peroxidase 4, the master 
regulator of ferroptosis.8 Coenzyme A is required to 
produce phosphatidylethanolamine, which is the main 
target for iron-induced peroxidation in ferroptosis.9 
Although it could be hypothesised that neuronal death 
in this disorder of neurodegeneration with brain iron 
accumulation is caused by ferroptotic cell death, patients 
with PKAN should be protected from ferroptosis because 
of these biochemical changes.
Given the challenges in implementing clinical trials in 
this population, we must glean as much information as 
possible from this trial about the efficacy of deferiprone. 
The uncertain role of iron in causing toxicity and the 
limitations of the primary outcome measure used in 
this study notwithstanding, there are certainly hints 
that deferiprone was beneficial: the treatment seemed 
to slow deterioration in patients with atypical PKAN; 
the extension phase showed evidence of slowed disease 
progression; and secondary analyses of the placebo-
controlled phase provided evidence that deferiprone 
might reduce the use of dystonia medication, freezing of 
gait, and cognitive impairment. Therefore, these results 
support the possibility that brain iron accumulation 
is indeed at least a component of patho genesis. 
The tolerability of deferiprone in this study supports 
conservative iron chelation as a therapy in patients with 
PKAN, given that there are no other treatment options. 
However, other potential biochemical consequences of 
the mutation also warrant investigation.
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Clinicians underestimate harms and overestimate bene-
fits from medical interventions.1 However, accord ing 
to a report by Rustam Al-Shahi Salman and colleagues2 
published in The Lancet Neurology, the perceived risk 
from restarting antiplatelet therapy after intracerebral 
haemorrhage in patients with cerebral microbleeds has 
been substantially overestimated on the basis of obser-
vational data. Use of antiplatelet therapy in patients with 
intracerebral haemorrhage is common,3 a conservative 
estimate is one in four patients, so more certainty in 
making decisions regarding restarting such therapy is 
highly relevant.
The RESTART trial,4 which is published in The Lancet, 
randomly assigned 537 survivors of intracerebral haem-
orrhage that occurred while taking antithrombotic ther-
apy to start or avoid antiplatelet therapy. The investi gators 
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reported no significant differences in risk of recurrent 
intracerebral haemorrhage but a reduced risk, albeit 
not reaching statistical signifi cance, of both haemor-
rhagic and ischaemic stroke was observed con sistently 
in subgroups in patients allocated to start anti platelet 
therapy.4 The neuroimaging substudy2 of the RESTART 
trial, published in The Lancet Neurology, focused on the 
254 patients with MRI performed be fore randomisation. 
By contrast with previous obser va tional data, there were 
no indications that starting anti platelet therapy increased 
risk of recurrent intra cerebral haemor rhage in patients 
with cerebral microbleeds or superficial siderosis. The 
number of microbleeds did not seem to affect risk of 
recurrent intracerebral haemorrhage. 
RESTART is the first randomised trial to address this 
subject; until now, data were based on observational 
hospital cohorts that suggested excess risk of recurrent 
intracerebral haemorrhage from reintroduction of anti-
platelets, with the highest risk in patients with cerebral 
microbleeds.5 Un certainty remains in relation to the pre-
cision of these findings. RESTART was under powered: 
a sample size of 2200 is suggested by the investigators 
as needed for a potentially conclusive study. However, 
findings were con sistent across prespecified subgroups. 
Selection bias towards small haematomas was present: 
median intracerebral haemorrhage volume was 3·7 mL 
in the intervention group and 4·3 mL in the control 
group, and few participants had high numbers of 
microbleeds. There was a predominance of men in 
the MRI substudy and entire cohort. Also, all MRI field 
strengths were accepted and gradient-recalled echo 
was used for bleeding detection, which most likely 
led to lower detection rates of cerebral microbleeds than 
what would have been the case if based on high field 
strengths or susceptibility weighted imaging, or both.6
Consequently, the results could be substantially dif-
ferent in an adequately powered trial and therefore the 
external validity of the results of the current substudy in 
relation to the overall intracerebral haemor rhage popula-
tion is unclear—for example, these results can not be 
directly extrapolated to patients with larger haematoma 
volumes or large numbers of microbleeds. However, the 
investigators have succeeded in recruiting a high-risk 
population; the proportion of recurrent intracerebral 
haem orrhage was 4·9% in the start antiplatelet therapy 
group versus 9·1% in the control group during an aver-
age follow-up of 2 years.2 Furthermore, con sideration of 
reinitiation of antiplatelet therapy is most pertinent in 
patients with small haematomas and good outcome.
These data are indeed surprising because most stroke 
clinicians would have expected that presence of cerebral 
microbleeds heralds higher risk of recurrent intracerebral 
haemorrhage on starting antiplatelet therapy, because 
the higher risk of intracerebral haem orrhage in patients 
with microbleeds has been well documented,7 and obser-
vational data support further increase in risk with use of 
antithrombotic drugs.5,8
That antiplatelet therapy increases risk of intra-
cerebral haemorrhage overall and that patients after 
intracerebral haemorrhage have high risk of recurrence 
do not necessarily imply that antiplatelet therapy will 
increase risk of intracerebral haemorrhage in this patient 
population. Furthermore, imaging findings such as the 
presence of microbleeds can often arouse concern, which 
can be worrying even in the absence of intracerebral 
haemorrhage—but possibly more for the clinician than 
for the patient’s prognosis. These findings underline 
that our pathophysiological understanding remains in-
complete and we should not rely on obser vational data, 
but always aim for randomised controlled data. More 
data are certainly needed in this field, including data on 
specific antiplatelet drugs and specific combinations of 
antiplatelet drugs that are frequently used—eg, stand-
ard regimens for acute coronary synd rome. Data from 
ran domised controlled trials are also needed for oral 
anticoagulants, for which a parallel discussion is ongoing.
My clinical interpretation of these results is that 
physi cians can be less restrictive in prescribing anti-
plate lets to patients with minor intracerebral haemor-
rhage. Decisions cannot be made on the basis of MRI 
findings such as cerebral microbleeds; according to 
these data, there is no excess risk attributed to the 
antiplatelet intervention in this population, so the focus 
of a therapeutic decision should rest not on the reasons 
to prescribe antiplate lets, but on the reasons not to 
prescribe them. How ever, the best evidence remains to 
be from randomised trials when available: RESTART-
Fr (NCT02966119) and STATICH (NCT03186729) are 
ongoing and might settle any remaining uncertainty. 
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Can cerebral microbleeds predict stroke recurrence?
Should patients with a history of ischaemic stroke 
or transient ischaemic attack be treated with anti-
thrombotic drugs? The answer to this question has been 
considered to be clear and straightforward for more 
than two decades.1,2 However, the question regarding 
the balance of future intracranial bleeding risk compared 
with risk of recurrent ischaemic stroke in patients with 
high burden of cerebral microbleeds remains one of the 
most complicated problems of modern stroke medicine.3
In The Lancet Neurology, Duncan Wilson and col leagues4 
aim to elucidate the association between cerebral 
microbleed burden in baseline neuroimaging and the 
risk of recurrent stroke. The study was a pooled analysis 
of individual patient data from 20 322 patients (mean 
age 70 years [SD 13]) with history of ischaemic stroke 
or transient ischaemic attack from 38 cohort studies.4 
After a cumulative follow-up of 35 225 patient-years 
(median 1·34 years [IQR 0·19–2·44]) the investi gators 
documented that cerebral microbleed pres ence in base-
line neuroimaging was associated with in creased risk for 
both ischaemic stroke and intracranial haemorrhage. 
Despite the fact that the adjusted hazard ratio (aHR) 
for intracranial haemorrhage was nearly five times 
higher than that for ischaemic stroke for patients with 
five or more or ten or more cerebral microbleeds and 
nearly eight times higher for patients with 20 or more 
cerebral microbleeds, the absolute rate of ischaemic 
stroke exceeded that of intracranial haemorrhage 
even in patients with high (≥20) cerebral micro-
bleed burden.4 Notably, all associations were inde pen-
dent from cerebral microbleed anatomical distribution 
(lobar vs mixed vs deep), antithrombotic treat ment 
(anti platelet or anti coagulant), ethnicity (white vs non-
white), age (>80 years vs ≤80 years), and the pres ence 
of white-matter hyperintensities on baseline neuro-
imaging or the diagnosis of probable cerebral amyloid 
angiopathy.4
The main strengths of this study are the large sample 
size, including almost all available findings from pub-
lished and unpublished cohort studies of adults with 
recent ischaemic stroke or transient ischaemic attack 
using appropriate MRI sequence sensitive to magnetic 
susceptibility, the prospective study design with strict 
inclusion and exclusion criteria, and the comprehensive, 
prespecified, and robust statistical analysis plan. This 
study offers novel and clinically relevant information 
that in patients with recent ischaemic stroke or transient 
ischaemic attack the absolute risk of ischaemic stroke is 
higher than that of intracranial haemorrhage, regardless 
of cerebral microbleed presence, burden, or pattern and 
independently of their secondary prevention treat ment 
with antiplatelets or oral anticoagulants. Notably, the 
individual-patient-data meta-analysis credibly contra-
dicts the findings of a previous meta-analysis that did 
not detect any association between cerebral micro-
bleed presence or burden and recurrent ischaemic stroke 
in patients with ischaemic stroke treated with oral 
anticoagulants.5
However, the observational study design is prone 
to residual confounding, and selection and indication 
biases. Furthermore, the investigators were unable to 
adjust for other cofounders in their multivariable models, 
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